Denali Therapeutics

Denali Therapeutics

DNLI· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -19.0% in FY2025

Ryan J. Watts, Ph.D. is the CEO of Denali Therapeutics and was paid $4.8M in FY2025 (Dec), down 28%.

Pay$100 in the stock at the end of FY20 → $20
CEO pay is from each Denali Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Ryan J. Watts, Ph.D.FY2025
  2. 2Alexander O. Schuth, M.D.FY2025
  3. 3Carole Ho, M.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Denali Therapeutics paid its 3 named executives $12.8M in total in FY2025 (Dec). CEO Ryan J. Watts, Ph.D. was paid $4.8M of that.

Name
Ryan J. Watts, Ph.D.President and Chief Executive Officer
Alexander O. Schuth, M.D.Chief Operating and Financial Officer and Secretary
Carole Ho, M.D.Chief Medical Officer and Head of Development (until November 14, 2025)

of each named executive, from the Summary Compensation Table of each proxy.

Peers23

See all

The FY2024 (Dec) proxy of Denali Therapeutics names 23 peer companies for pay. Among Denali Therapeutics and these peers, CEO pay was 9th highest of 11 and total shareholder return was 3rd highest of 11.

9th highest of 11in Denali Therapeutics and its pay peers, FY2024 (Dec) by CEO pay:

$2.0M$33.2M

3rd highest of 11in Denali Therapeutics and its pay peers, FY2024 (Dec) by total shareholder return:

$58$443

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Julian C. BakerChair · 0 yr on the boardIndependentCorporate Governance and Nominating—Paid as an executive
  • Jennifer CookDirector · 7 yr on the boardIndependentCorporate Governance and Nominating (Chair)—Paid as an executive
  • Peter KleinDirector · 7 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
  • Steve Krognes, M.B.A.Director · 3 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Denali Therapeutics CEO pay fell 28% to $4.8M. The stock fell 19% in FY2025 (Dec).
    DEF 14A
  2. Board
    Julian C. Baker joined the board of Denali Therapeutics. Julian C. Baker sits on no other public board.
    3
  3. Pay
    Denali Therapeutics CEO pay fell 17% to $6.6M. The stock fell 5% in FY2024 (Dec).
    DEF 14A
  4. Pay
    Denali Therapeutics CEO pay fell 15% to $7.9M. The stock fell 23% in FY2023 (Dec).
    DEF 14A
  5. Pay
    Denali Therapeutics CEO pay fell 27% to $9.3M. The stock fell 38% in FY2022 (Dec).
    DEF 14A
  6. Pay
    Denali Therapeutics Division head pay fell 27% to $4.2M. The stock fell 23% in FY2023 (Dec).
    DEF 14A
  7. Pay
    Denali Therapeutics Division head pay fell 13% to $5.7M. The stock fell 38% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Denali Therapeutics Chief Operating and Financial Officer and Secretary pay fell 27% to $4.2M. The stock fell 23% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Denali Therapeutics Chief Operating and Financial Officer and Secretary pay fell 13% to $5.7M. The stock fell 38% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 21, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 17, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 18, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data